Topical anti-inflammatory activity of <it>Polygonum cuspidatum </it>extract in the TPA model of mouse ear inflammation

• Main Authors: Wicker Louise (Author), Hargrove James L (Author), Greenspan Phillip (Author), Bralley Eve E (Author), Hartle Diane K (Author)
• Format: Book
• Published: BMC, 2008-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/1476-9255-5-1; 1476-9255
• Keywords: Therapeutics. Pharmacology; RM1-950
• Source: Journal of Inflammation, Vol 5, Iss 1, p 1 (2008)

<p>Abstract</p> <p>Background</p> <p>This study tested the ability of a characterized extract of <it>Polygonum cuspidatum </it>(PCE) to inhibit mouse ear inflammation in response to topical application of 12-<it>O-</it>tetradecanoylphorbol-13-acetate (TPA).</p> <p>Methods</p> <p>A 50% (wt:vol) ethanolic solution of commercial 200:1 PCE was applied to both ears of female Swiss mice (n = 8) at 0.075, 0.15, 0.3, 1.25 and 2.5 mg/ear 30 min after TPA administration (2 μg/ear). For comparison, 3 other groups were treated with TPA and either 1) the vehicle (50% ethanol) alone, 2) indomethacin (0.5 mg/ear), or 3) <it>trans</it>-resveratrol (0.62 mg/ear). Ear thickness was measured before TPA and at 4 and 24 h post-TPA administration to assess ear edema. Ear punch biopsies were collected at 24 h and weighed as a second index of edema. Myeloperoxidase activity was measured in each ear punch biopsy to assess neutrophil infiltration.</p> <p>Results</p> <p>PCE treatment at all doses significantly reduced ear edema compared to the TPA control. The PCE response was dose-dependent and 2.5 mg PCE significantly inhibited all markers of inflammation to a greater extent than indomethacin (0.5 mg). MPO activity was inhibited at PCE doses ≥ 1.25 mg/ear. <it>Trans-</it>resveratrol inhibited inflammation at comparable doses.</p> <p>Conclusion</p> <p>PCE inhibits development of edema and neutrophil infiltration in the TPA-treated mouse ear model of topical inflammation.</p>